

Jos Vicente Fernandez-Montero

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/8114393/jose-vicente-fernandez-montero-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

348
citations

11
h-index

18
g-index

20
ext. papers

382
ext. citations

4
avg, IF

3.06
L-index

#	Paper	IF	Citations
19	Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1549-53	11.6	60
18	Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1161-70	4	45
17	Update on HIV/HCV coinfection. <i>Current HIV/AIDS Reports</i> , 2013 , 10, 226-34	5.9	42
16	HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1615-29	4	31
15	Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014 , 105, 1-7	10.8	23
14	Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013 , 27, 1129-34	3.5	21
13	Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfecting patients. <i>Aids</i> , 2013 , 27, 1187-8	3.5	20
12	Emerging antiretroviral drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 211-9	4	18
11	Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2015 , 20, 65-72	1.6	15
10	Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2012 , 26, 517-30	2.5	13
9	Predicted effect of direct acting antivirals in the current HIV-HCV-coinfecting population in Spain. <i>Antiviral Therapy</i> , 2012 , 17, 571-5	1.6	13
8	Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1007-14	4	11
7	Antiretroviral drugs for pre-exposure prophylaxis of HIV infection. <i>AIDS Reviews</i> , 2012 , 14, 54-61	1.5	10
6	Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1051-7	4	8
5	Progression to advanced liver fibrosis in HIV-HCV-coinfecting patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014 , 19, 799-803	1.6	8
4	Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era. <i>Infectious Disease Clinics of North America</i> , 2012 , 26, 931-48	6.5	7
3	Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013 , 12, 269-275		3

2 Authors response: expert reviews: who are they for?. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 1217-8

1 Long-term treatment of patients with HIV-1: the role of atazanavir. *HIV/AIDS - Research and Palliative Care*, **2010**, 2, 157-66

1.2